Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

START BREAKING TRADITION

Instead of an ICS/LABA, start appropriate symptomatic patients with COPD on ANORO for dual bronchodilation

WHO IS RIGHT FOR ANORO?

Your symptomatic patient may be ready for ANORO.

SEE WHY NOW >

WHO IS RIGHT FOR ANORO?

Your symptomatic patient may be ready for ANORO.

SEE WHY NOW >

ANORO is for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

ANORO is NOT for the relief of acute bronchospasm or for asthma.

ANORO was studied in patients with moderate or worse COPD.

LUNG FUNCTION VS ICS/LABA

The evidence speaks for itself.

SEE THE DETAILS >

DUAL BRONCHODILATION

The 2 components work together to increase bronchodilation.

SEE HOW IT WORKS >

SAMPLE THE POSSIBILITIES

ORDER SAMPLES >

ICS/LABA=inhaled corticosteroid/long-acting beta2-adrenergic agonist.